CN103614352B - 一种高效重组表达透明质酸酶的方法 - Google Patents
一种高效重组表达透明质酸酶的方法 Download PDFInfo
- Publication number
- CN103614352B CN103614352B CN201310597818.1A CN201310597818A CN103614352B CN 103614352 B CN103614352 B CN 103614352B CN 201310597818 A CN201310597818 A CN 201310597818A CN 103614352 B CN103614352 B CN 103614352B
- Authority
- CN
- China
- Prior art keywords
- unidasa
- hyaluronidase
- seq
- gene
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 108010003272 Hyaluronate lyase Proteins 0.000 title claims abstract description 14
- 102000001974 Hyaluronidases Human genes 0.000 title claims abstract description 12
- 229960002773 hyaluronidase Drugs 0.000 title abstract description 9
- 238000003259 recombinant expression Methods 0.000 title abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 39
- 239000002773 nucleotide Substances 0.000 claims abstract description 14
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 14
- 238000000746 purification Methods 0.000 claims abstract description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 17
- 229920002674 hyaluronan Polymers 0.000 claims description 17
- 229960003160 hyaluronic acid Drugs 0.000 claims description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
- 241001506991 Komagataella phaffii GS115 Species 0.000 claims description 11
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 238000011144 upstream manufacturing Methods 0.000 claims description 10
- 238000000855 fermentation Methods 0.000 claims description 8
- 230000004151 fermentation Effects 0.000 claims description 8
- 108091008146 restriction endonucleases Proteins 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 5
- 241000235648 Pichia Species 0.000 claims description 5
- 229910052759 nickel Inorganic materials 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 5
- 230000006798 recombination Effects 0.000 claims description 5
- 238000005215 recombination Methods 0.000 claims description 5
- 230000003321 amplification Effects 0.000 claims description 4
- 230000029087 digestion Effects 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims description 3
- 150000002460 imidazoles Chemical class 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000002054 inoculum Substances 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000012531 culture fluid Substances 0.000 claims description 2
- 238000013461 design Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 238000010353 genetic engineering Methods 0.000 claims description 2
- 238000011218 seed culture Methods 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 241000235058 Komagataella pastoris Species 0.000 abstract description 5
- 230000003248 secreting effect Effects 0.000 abstract description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- 229940088598 enzyme Drugs 0.000 description 18
- 239000006228 supernatant Substances 0.000 description 16
- 241000545744 Hirudinea Species 0.000 description 15
- 239000012530 fluid Substances 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- LWFUFLREGJMOIZ-UHFFFAOYSA-N 3,5-dinitrosalicylic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O LWFUFLREGJMOIZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930003756 Vitamin B7 Natural products 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000011735 vitamin B7 Substances 0.000 description 2
- 235000011912 vitamin B7 Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000006098 transglycosylation Effects 0.000 description 1
- 238000005918 transglycosylation reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (3)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310597818.1A CN103614352B (zh) | 2013-08-15 | 2013-11-22 | 一种高效重组表达透明质酸酶的方法 |
US14/251,579 US9279111B2 (en) | 2013-07-29 | 2014-04-12 | Leech hyaluronidase and its application |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013103585737 | 2013-08-15 | ||
CN201310358573.7 | 2013-08-15 | ||
CN2013103585737A CN103436508A (zh) | 2013-08-15 | 2013-08-15 | 一种高效重组表达透明质酸酶的方法 |
CN201310597818.1A CN103614352B (zh) | 2013-08-15 | 2013-11-22 | 一种高效重组表达透明质酸酶的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103614352A CN103614352A (zh) | 2014-03-05 |
CN103614352B true CN103614352B (zh) | 2015-07-08 |
Family
ID=49690225
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013103585737A Pending CN103436508A (zh) | 2013-07-29 | 2013-08-15 | 一种高效重组表达透明质酸酶的方法 |
CN201310597818.1A Active CN103614352B (zh) | 2013-07-29 | 2013-11-22 | 一种高效重组表达透明质酸酶的方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013103585737A Pending CN103436508A (zh) | 2013-07-29 | 2013-08-15 | 一种高效重组表达透明质酸酶的方法 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN103436508A (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103695448B (zh) * | 2013-07-29 | 2016-08-17 | 江南大学 | 一种透明质酸酶编码基因及其发酵生产和纯化方法 |
CN103484513B (zh) * | 2013-10-22 | 2015-02-11 | 江南大学 | 一种酶法制备小分子寡聚透明质酸的方法 |
CN104178539B (zh) * | 2014-08-19 | 2017-11-21 | 江南大学 | 一种规模化制备特定分子量小分子透明质酸的方法 |
CN104212732A (zh) * | 2014-09-12 | 2014-12-17 | 江南大学 | 一种产透明质酸的重组毕赤酵母及其构建方法 |
CN104232804B (zh) * | 2014-10-08 | 2016-03-23 | 江南大学 | 一种梯度变温诱导提高透明质酸酶表达量的方法 |
CN104278005A (zh) * | 2014-10-17 | 2015-01-14 | 江南大学 | 一种表达透明质酸酶的重组枯草芽孢杆菌 |
CN107988184A (zh) * | 2017-12-22 | 2018-05-04 | 广州白云山拜迪生物医药有限公司 | 一种重组人透明质酸酶的纯化方法 |
CN108355618B (zh) * | 2018-02-27 | 2020-09-08 | 江南大学 | 牛来源透明质酸酶亲和介质及其吸附方法 |
CN114350691B (zh) * | 2021-03-05 | 2023-12-08 | 华熙生物科技股份有限公司 | 一种高效表达透明质酸水解酶的基因及其表达方法 |
CN114350535B (zh) * | 2021-10-09 | 2024-06-21 | 华熙生物科技股份有限公司 | 一种高产透明质酸酶的工程酵母菌株及其应用 |
CN117165558B (zh) * | 2023-09-27 | 2024-07-09 | 四川德博尔制药有限公司 | 一种透明质酸酶的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101633931A (zh) * | 2008-07-25 | 2010-01-27 | 山东省生物药物研究院 | 一种透明质酸酶表达载体及其应用 |
-
2013
- 2013-08-15 CN CN2013103585737A patent/CN103436508A/zh active Pending
- 2013-11-22 CN CN201310597818.1A patent/CN103614352B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101633931A (zh) * | 2008-07-25 | 2010-01-27 | 山东省生物药物研究院 | 一种透明质酸酶表达载体及其应用 |
Non-Patent Citations (2)
Title |
---|
透明质酸制备方法及应用研究的进展;朱广华等;《中国医药工业杂志》;19961231;第2卷(第8期);第382-384页 * |
透明质酸合成酶的研究进展;葛昊等;《药学进展》;20081231;第32卷(第7期);第297页左栏第2段-第298页左栏第1段 * |
Also Published As
Publication number | Publication date |
---|---|
CN103614352A (zh) | 2014-03-05 |
CN103436508A (zh) | 2013-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103614352B (zh) | 一种高效重组表达透明质酸酶的方法 | |
CN104263707A (zh) | 一种提高毕赤酵母重组表达透明质酸酶的方法 | |
CN103695448B (zh) | 一种透明质酸酶编码基因及其发酵生产和纯化方法 | |
CN104278005A (zh) | 一种表达透明质酸酶的重组枯草芽孢杆菌 | |
CN109912700B (zh) | 一种利用β-1,6葡聚糖酶联产酵母葡聚糖、甘露糖蛋白和酵母提取物的方法 | |
CN103484513B (zh) | 一种酶法制备小分子寡聚透明质酸的方法 | |
CN104263666B (zh) | 一种产小分子透明质酸的重组毕赤酵母及其构建方法 | |
CN114350691A (zh) | 一种高效表达透明质酸水解酶的基因及其表达方法 | |
CN110093331A (zh) | 一种高产的耐高温宽pH稳定性的甘露聚糖酶ManGold及基因与应用 | |
CN106995811A (zh) | 一种褐藻胶裂解酶、其制备方法及应用 | |
CN104745553A (zh) | 重组人透明质酸酶及其制备方法和采用聚乙二醇共价修饰的化合物和方法 | |
CN105441464A (zh) | 一种葡聚糖外切酶ii基因的密码子优化及其毕赤酵母表达系统 | |
CN107893061A (zh) | 一种米黑根毛霉来源的β‑1,3‑葡聚糖酶及其应用 | |
CN114350639A (zh) | 一种密码子优化的透明质酸水解酶基因及其表达 | |
CN104178539B (zh) | 一种规模化制备特定分子量小分子透明质酸的方法 | |
CN105039371A (zh) | 海藻糖合成酶-海藻糖水解酶融合酶及其表达基因与应用 | |
CN101139556B (zh) | 重组α-葡聚糖酶融合蛋白高效生产方法及相关表达载体和菌株 | |
CN103952326B (zh) | 一种共表达菊粉外切酶和内切酶的重组毕赤酵母菌株及其构建方法与应用 | |
CN109652437A (zh) | 一种产壳聚糖酶的重组菌的构建方法及其应用 | |
CN105567779A (zh) | 一种高产低分子量热凝胶的发酵方法 | |
CN103146726B (zh) | 一种黑曲霉α-葡萄糖苷酶基因及其高效表达方法 | |
CN110093326B (zh) | 一种胞外AA9家族多糖单加氧酶EpLPMOa及其应用 | |
CN108865913B (zh) | 一种构建高效分泌表达硫酸软骨素水解酶重组菌的方法 | |
CN107418941A (zh) | 一种重组黄曲霉壳聚糖酶和编码基因及制备和应用 | |
CN113862240B (zh) | 一种密码子优化的糖苷酶swmu-f2-2及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Jian Inventor after: Du Guocheng Inventor after: Kang Zhen Inventor after: Li Jianghua Inventor after: Jin Peng Inventor before: Chen Jian Inventor before: Du Guocheng Inventor before: Kang Zhen Inventor before: Jin Peng |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: CHEN JIAN DU GUOCHENG KANG ZHEN JIN PENG TO: CHEN JIAN DU GUOCHENG KANG ZHEN LI JIANGHUA JIN PENG |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140305 Assignee: NANJING HANXIN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Assignor: Jiangnan University Contract record no.: X2020320000330 Denomination of invention: An efficient method for recombinant expression of hyaluronidase Granted publication date: 20150708 License type: Common License Record date: 20201212 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140305 Assignee: Nanjing letao Biotechnology Co.,Ltd. Assignor: Jiangnan University Contract record no.: X2023980034160 Denomination of invention: A highly efficient method for recombinant expression of hyaluronidase Granted publication date: 20150708 License type: Common License Record date: 20230328 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140305 Assignee: Shuiyang Cosmetics Manufacturing Co.,Ltd. Assignor: Jiangnan University Contract record no.: X2024980001575 Denomination of invention: An efficient method for recombinant expression of hyaluronidase Granted publication date: 20150708 License type: Common License Record date: 20240130 |
|
EE01 | Entry into force of recordation of patent licensing contract |